We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
OnCare is a digital care management software that is digitising elderly care, creating a global care marketplace via the OpenTable model to care. OnCare provides care agencies with the power to plan, manage and enhance care delivery and staff communication. Their mission is to make care easier for everyone. OnCare is currently live with over 110 home-care agencies around the UK, and more than 1100 care workers. The company is planning to enter markets of Hong Kong, Canada and Israel. With the proceeds, the company will use this fund for people, office space, technology, software, hosting and marketing.

Pitch Rated

72%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £96,040
Sol-Gel Materials and Application (SGMA) is a sustainable technology company that is using its new sol-gels to create sustainable solutions to plastic environmental waste. The company has researched and developed a non-plastic, non-toxic coating for products, from food packaging to electronics, that is water and oil resistant yet recyclable. Its product is the world’s only biodegradable, compostable, and recyclable (BCR) solution. The company's founder and CEO, Dr Fanya Ismail, has won the award 'Women in Innovation 2019' by Innovate UK and the company's work has been covered by BBC South East Today. The company plans to function as an IP management company, sub-contract manufacturing to chemical firms moving from bulk to advanced materials, and outsource distribution to partners, whose packaging customers serve brand owners.

Pitch Rated

72%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £611,040
Nikalyte is a specialist in nanoparticles research and development (R&D) as well as commercialisation in various application areas such as cell binding, cell separation, drug delivery, catalysis, nano-photonics, and electrochemistry. The company is developing a nanoparticle generator, which will enable researchers to produce nanoparticles of almost any metal or alloy on almost any substrate via a user-friendly interface. Nikalyte is offering free nanoparticle samples to researchers investigating antiviral materials, such as Copper and Silver, towards developing a vaccine for Covid-19. The company also offers a consultancy service that provides advice on nanoparticle applications and ultra-high vacuum systems. The company aims to use the investment to scale its business.

Pitch Rated

37%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
GymBuddy is an online platform that enables consumers to find, book, and attend a gym location, services, or products offered and operated by fitness studios, gyms, trainers, venues, or other third parties. Users can easily, through filtered searches on the app, view descriptions, and contact information of specialists within the fitness industry such as personal trainers, nutritionists, and physiotherapists. The UK fitness industry alone is currently worth over £5 billion. Based on recent statistics, the average gym membership in the UK costs members £40 a month, which often ties them into lengthy contracts. The GymBuddy app will enter the Health & Fitness club sector as a multi-gym membership feature that gives users access to gyms and various fitness plans, without the need for bricks-and-mortar locations under its brand. The company is seeking an investment of £400,000 to expand its brand identity and bring more users to its ecosystem to generate profits.

Pitch Rated

30%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Lighting Design, Luminaire Development and UK Manufacture. Our core products are street/ industrial lighting. LED lighting is the future and ALed's will continue to design and develop ground breaking products that challenge. Our design technology means we provide highly efficient lighting solutions that maintain a quality of light far longer than our competition. A £1.5 Billion spend on street lighting upgrades (UK) planned by 2020 provides the market for our continued growth.
days to go: Expired investment: £393,256
Aiming to prevent further deterioration and leakage of water and sewerage pipes, Aqualiner has developed their Melt in Place Pipe (MIPP). This patented technology consists of a sock insertion, which when heated, expands and melts onto the inner pipe and forms a solid glass-reinforced thermoplastic layer. This process can increase the longevity of existing pipes and is the only product of this type to be approved to be safe-for-use in drinking water pipes. The UK has more than 251,000 miles of water pipes, where almost 75,000 miles of pipes are classed as damaged. Aqualiner firstly plans to sell the initial equipment in return for a small profit margin, but the materials and consumables used in the process will be sold to the licensed contractor directly as a second income stream. The third source of revenue is derived from fees charged to International territorial licensors for any Aqualiner sales. The product has been developed with support from Anglian Water, Severn Trent Water and Yorkshire Water and is approved to be installed in US drinking water pipes.
days to go: Expired investment: £642,471
Carnot is developing hydrogen engines with key components manufactured from ceramics able to withstand fuel combustion temperatures, eliminating the need for cooling systems and doubling the efficiencies of modern engines. The company argues that modern engines waste on average one-third of fuel energy to cool systems that stop metallic components from melting. Carnot claims that its engines eliminate this waste doubling efficiency, halve fuel costs and CO2 and achieve net-zero operation by operating on biofuels and hydrogen benefiting the long haul transport, marine and primary off-grid power markets. Carnot has raised over £600,000 including a pre-seed round in 2020 for £357,000 at a pre-money valuation of £2 million, a £300,000 Innovate UK grant and another £300,000 Eureka Eurostar’s grant. Carnot has a 5-year, 3-phase exit strategy and will begin licensing its IP at the end of 2023 at which point it will begin generating revenue. It will eventually look for acquisition from one of its manufacturing partners in 2025 after demonstrating industry acceptance of its technology.
days to go: Expired investment: £262,500
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph